A study was conducted to assess the association between health care costs and patient adherence to aminosalicylate pharmacotherapy for digestive disorders.
You are here
P&T® Journal contents for November 2006
The Neurotoxin Spasticity Consensus Group presents its findings on botulinum toxin in the treatment of various conditions characterized by muscle overactivity.
The safety and efficacy of ACE-inhibitors (ramipril, perindopril, and trandolapril), an angiotensin-receptor blocker (valsartan), an anticoagulant/antiplatelet combination, and a direct renin inhibitor (aliskiren) are reviewed.
The authors report on ceftaroline for skin and skin-structure infections; cethromycin for acute bacterial exacerbations of chronic bronchitis; tigecycline for community-acquired pneumonia; ceftobiprole for skin infections; moxifloxacin for leprosy; telithromycin for acute bacterial sinusitis; oseltamivir to reduce pneumonia risk following pediatric influenza; a human papillomavirus vaccine; and micafungin for invasive candidiasis in children.
Three agents are discussed: posaconazole oral suspension (Noxafil) for Aspergillus and Candida infections; Travoprost Z ophthalmic solution (Travatan Z), for glaucoma or ocular hypertension; and arformoterol tartrate inhalation solution (Brovana) for obstructive pulmonary disease, chronic bronchitis, and emphysema.